Press "Enter" to skip to content

FDA approves expanded label for Regeneron/Sanofi’s Dupixent

The U.S. Food and Drug Administration on Wednesday approved Regeneron Pharmaceuticals Inc and Sanofi SA’s drug Dupixent to treat nasal polyps, marking the third major use for the injectable medicine.

Original source:

Also Read:   Canada ramps up battle against virus, slashes rates and promises stimulus